Replies to post #112863 on Biotech Values

[DewDiligence]

I don’t expect the various outcomes mentioned in #msg-58972671 to move MNTA’s share price quite as much as you do. Many investors remain unconvinced that NVS/MNTA will receive FDA approval for generic Copaxone before Teva’s patents expire in 2014; for those investors, the patent case is mostly academic.